Boron Containing Patents (Class 548/405)
  • Patent number: 10696695
    Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 30, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Alexandra M. Courtis, James Adam Hendricks
  • Patent number: 10586702
    Abstract: Using processes disclosed herein, materials and structures are created and used. For example, processes can include melting boron nitride or amorphous carbon into an undercooled state followed by quenching. Exemplary new materials disclosed herein can be ferromagnetic and/or harder than diamond. Materials disclosed herein may include dopants in concentrations exceeding thermodynamic solubility limits. A novel phase of solid carbon has structure different than diamond and graphite.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: March 10, 2020
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventor: Jagdish Narayan
  • Patent number: 10519394
    Abstract: A method for preventing or reducing low speed pre-ignition in an engine lubricated with a lubricating oil while maintaining or improving cleanliness by using as the lubricating oil a formulated oil. The formulated oil has a composition including a lubricating oil base stock as a major component, and at least one boron-containing compound and at least one overbased calcium detergent as minor components. The at least one boron-containing compound includes at least one borated dispersant, or a mixture of a boron-containing compound and a non-borated dispersant. The boron to nitrogen ratio for the at least one boron-containing compound is less than or equal to about 0.3 and the lubricating oil is essentially free of elemental magnesium. The lubricating oils of this disclosure are particularly advantageous as passenger vehicle engine oil (PVEO) products.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 31, 2019
    Assignee: ExxonMobil Research and Engineering Company
    Inventors: Smruti A. Dance, Douglas E. Deckman, Raymond G. Burns, III
  • Patent number: 10294249
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 21, 2019
    Assignee: Qpex Biopharma, Inc.
    Inventors: Scott J. Hecker, Raja K. Reddy, Tomasz Glinka, Olga Rodny
  • Patent number: 10202538
    Abstract: The present invention provides a method for inhibiting structure II (sII) gas hydrate formation which comprises treating (i) a gas hydrate inhibitor and (ii) at least one additive selected from the group consisting of N-hexyl-N-methyl-pyrrolidinium tetrafluoroborate (HMP-BF4), M-hydroxyethyl-N-methyl-pyrrolidinium tetrafluoroborate (HEMP-BF4), N-ethyl-N-methyl-immidazolium tetrafluoroborate (EMIM-BF4) and N-ethyl-N-methyl-pyrrolidinium tetrafluoroborate (EMP-BF4) in water, which is in contact with a gas mixture of forming structure II gas hydrate. The additives according to the present invention can exhibit the same or greater effects of inhibiting the formation of the structure II gas hydrate through an interaction, even when the amount of a gas hydrate inhibitor is reduced.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: February 12, 2019
    Inventors: Seong-Pil Kang, Kisub Kim, Jong-Nam Kim
  • Patent number: 10005793
    Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein: (a) is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 26, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Alexandra M. Courtis, James Adam Hendricks
  • Patent number: 9862846
    Abstract: A printable ink for electronic applications is disclosed. The ink contains at least one non-interactive solvent, a binder, optionally one or more particulate fillers that may be conductive, semi-conductive or non-conductive, optionally a co-solvent and optionally other additives.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: January 9, 2018
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: David Andrew Greenhill, Vincenzo Arancio, Jay Robert Dorfman
  • Patent number: 9741950
    Abstract: The invention provides a polycyclic aromatic compound or a salt thereof having a partial structure represented by the following general formula (I): wherein X, ring A, ring B, ring C, and ring D are as defined in the specification.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 22, 2017
    Assignees: KYOTO UNIVERSITY, JNC CORPORATION
    Inventors: Takuji Hatakeyama, Masaharu Nakamura, Sigma Hashimoto
  • Patent number: 9399059
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: July 26, 2016
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Patent number: 9388361
    Abstract: A lubricating oil additive composition contains a borated succinimide derivative and an amino alcohol compound. A lubricating oil composition containing the lubricating oil additive composition is excellent in high-temperature detergency and base value retention (long-drain capabilities) even though a blended content of a metal detergent is low and an ash content is small.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 12, 2016
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Izumi Terada, Junya Iwasaki
  • Patent number: 9252371
    Abstract: An organic photoelectronic device includes a first electrode and a second electrode facing each other, and an active layer between the first electrode and the second electrode and including a first compound represented by Chemical Formula 1 or 2, and a ratio between a FWHM of a light absorption curve depending on a wavelength of the first compound in a solution state and in a thin film state satisfies the following Relationship Equation 1: FWHM2/FWHM1<2.5. In the Relationship Equation 1, FWHM1 is a FWHM of the light absorption curve depending on a wavelength in a solution state, and FWHM2 is a FWHM of the light absorption curve depending on a wavelength in a thin film state.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: February 2, 2016
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Tadao Yagi, Sakurai Rie, Kwang Hee Lee, Dong-Seok Leem, Xavier Bulliard, Ryuichi Satoh, Kyung Bae Park, Sung Young Yun, Gae Hwang Lee, Yong Wan Jin, Chul Joon Heo
  • Patent number: 9222043
    Abstract: Marking a petroleum product includes adding a covert dye selected from the group consisting of azadipyrromethene dyes, dipyrromethene dyes, and any combination thereof to the petroleum product and distributing the dye in the petroleum product. A petroleum product selected for analysis may be spectroscopically analyzed for the presence of an azadipyrromethene dye, a dipyrromethene dye, or a combination thereof. A concentration of at least one azadipyrromethene or dipyrromethene dye present in the portion of the petroleum product may be determined to identify the petroleum product as counterfeit, adulterated, or authentic based on the determined concentration of the azadipyrromethene or dipyrromethene dye.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: December 29, 2015
    Assignee: Authentix, Inc.
    Inventors: Philip B. Forshee, Greg R. Hundt, Jeffrey L. Conroy
  • Patent number: 9216212
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: December 22, 2015
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Patent number: 9090841
    Abstract: Method of marking a hydrocarbon liquid includes adding to the liquid a tracer compound of Formula I: wherein, each X is independently hydrogen, bromine, fluorine, a halogenated alkyl group, a linear, branched or cyclic C1-C20 alkyl group, or a phenyl group substituted with one or more halogen atoms, an alkyl group or a halogenated alkyl group; each Y is independently bromine, fluorine, a halogenated alkyl group, a branched or cyclic C1-C9 alkyl group, or a phenyl group substituted with at least one alkyl and/or a halogenated alkyl group; Z is a phenyl group substituted with one or more halogen atoms, an aliphatic or halogenated aliphatic group, a halogenated alkyl group or a linear, branched or cyclic C1-C20 alkyl group, provided that when each Y is a fluorine atom, Z is not a linear or branched C1-C20 alkyl group.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: July 28, 2015
    Assignee: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
    Inventors: Duncan William John McCallien, Ian Stuart Edworthy, Vincent Brian Croud
  • Patent number: 9040718
    Abstract: Compounds (including polymers) for use in hybrid host materials which can be used in electroluminescent devices. The compounds comprise at least one electron-transporting moiety and at least one hole-transporting moiety which are joined by a flexible linker. Hybrid host materials comprising the compounds exhibit stability against phase separation, elevated glass transition temperature, morphological stability against crystallization, and isolation of the electron transporting moiety and hole transporting moiety ?-systems.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: May 26, 2015
    Assignee: The University of Rochester
    Inventors: Shaw H. Chen, Lichang Zeng, Thomas Yung-Hsin Lee
  • Publication number: 20150141660
    Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 21, 2015
    Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
  • Publication number: 20150119364
    Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
    Type: Application
    Filed: November 10, 2014
    Publication date: April 30, 2015
    Inventors: Stephen J. BAKER, Tsutomu Akama, Michael Richard Kevin Alley, Stephen J. Benkovic, Michael DiPierro, Vincent S. Hernandez, Karin M. Hold, Isaac Kennedy, Igor Likhotvorik, Weimin Mao, Kirk Maples, Jacob J. Plattner, Fernando Rock, Virginia Sanders, Aaron M. Stemphoski, George Petros Yiannikouros, Siead Zegar, Yong-Kang Zhang, Huchen Zhou
  • Patent number: 9012658
    Abstract: Provided are methods for making and using chiral, non-racemic protected organoboronic acids, including pinene-derived iminodiacetic acid (PIDA) boronates, to direct and enable stereoselective synthesis of organic molecules. Also provided are methods for purifying PIDA boronates from solution. Also provided are methods for deprotection of boronic acids from their PIDA ligands. The purification and deprotection methods may be used in conjunction with methods for coupling or otherwise reacting boronic acids. Iterative cycles of deprotection, coupling, and purification can be performed to synthesize chiral, non-racemic compounds. The methods are suitable for use in an automated chemical synthesis process. Also provided is an automated small molecule synthesizer apparatus for performing automated stereoselective synthesis of chiral, non-racemic small molecules using iterative cycles of deprotection, coupling, and purification.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 21, 2015
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Martin D. Burke, Junqi Li, Eric P. Gillis
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Publication number: 20150105562
    Abstract: The present invention relates to a method for preparing borinic acid derivatives and novel borinic acid derivatives. The preparing method of the present invention provides borinic acid derivatives of general formula (2): (Ar?2B(OH) ??(2) wherein Ar is the same as defined in the description and claims, selectively and in a high yield by reacting a compound of general formula (1): Ar-M, ??(1) wherein Ar and M are the same as defined in the description and claims, with tri-t-butyl borate and then hydrolyzing the reaction product.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 16, 2015
    Applicant: MANAC INC.
    Inventors: Satoshi Murakami, Takayuki Suzuki
  • Patent number: 9006457
    Abstract: The invention relates to reactive ionic liquids containing organic cations with groups or substituents which are susceptible to electrochemical reduction and anions obtained from fluoroalkyl phosphates, fluoroalkyl phosphinates, fluoroalkyl phosphonates, acetates, triflates, imides, methides, borates, phosphates and/or aluminates, for use in electrochemical cells, such as lithium ion batteries and double-layer capacitors.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: April 14, 2015
    Assignee: BASF SE
    Inventors: Michael Schmidt, Nikolai (Mykola) Ignatyev, William-Robert Pitner
  • Publication number: 20150097162
    Abstract: Provided is an organic electroluminescent element which has improved driving voltage and improved current efficiency. An organic electroluminescent element having the above-mentioned improved characteristics is provided by using, as a material for organic electroluminescent elements, a polycyclic aromatic compound in which a nitrogen atom and another heteroatom or a metal atom (X) are adjacent to each other in a non-aromatic ring.
    Type: Application
    Filed: September 11, 2013
    Publication date: April 9, 2015
    Applicants: JNC Corporation, Kyoto University
    Inventors: Yohei Ono, Kazushi Shiren, Toshiaki Ikuta, Jingping Ni, Takeshi Matsushita, Takuji Hatakeyama, Masaharu Nakamura, Shiguma Hashimoto
  • Patent number: 8993781
    Abstract: The invention relates to novel fluorescent compounds derived from non-fluorinated dipyrromethene-boron, to a method for preparing same and to the use thereof for the fluorescent marking of biological molecules. The invention also relates to biological molecules marked with said fluorescent compounds, and to the use thereof in detection methods such as medical diagnosis methods. More particularly, the detection methods of the invention are particularly useful for diagnosing neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: March 31, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite de Strasbourg
    Inventors: Jean De Barry, Corinne Liegeois, Alexandre Haefele, Thomas Bura, Gilles Ulrich, Raymond Ziessel
  • Publication number: 20150080341
    Abstract: The inventive boronic acid analogs are potent inhibitors of Arginase I and II activity. These compounds are candidate therapeutics for treating a disease or disorder associated with an imbalance in the activity or concentration of cellular arginase I and arginase II enzymes. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the compositions for therapy.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Michael Van Zandt, Gunnar Erik Jagdmann, JR.
  • Patent number: 8981147
    Abstract: The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: March 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mitsuhisa Yamano, Mitsutaka Goto, Shinji Kawaguchi, Masatoshi Yamada, Jun-ichi Kawakami
  • Publication number: 20150065729
    Abstract: A compound comprising a boron subphthalocyanine moiety, a plurality of solubilizing substituents positioned on peripheral cyclic groups of the boron subphthalocyanine moiety and an axial substituent positioned on the boron atom of the boron subphthalocyanine moiety. The plurality of solubilizing substituents comprise an oxygen or sulfur containing functional group and a substituted or unsubstituted, linear, branched or cyclic, aliphatic or aromatic terminal hydrocarbyl group that is 8 or more carbon atoms in length, the hydrocarbyl group optionally containing one or more heteroatoms. The axial substituent is selected from the group consisting of halogen, alkyloxy, haloalkyloxy, ester, carbonyl substituted alkyl, carbonyl substituted haloalkyl, alkylaryloxy, haloalkylaryloxy, alkyl sulfonyl, haloalkyl sulfonyl, alkylaryl sulfonyl and haloalkylaryl sulfonyl.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 5, 2015
    Applicant: XEROX CORPORATION
    Inventors: Jeffrey H. Banning, Wolfgang G. Wedler, Stephan V. Drappel
  • Publication number: 20150065713
    Abstract: A compound comprising a boron subphthalocyanine moiety, a plurality of solubilizing substituents positioned on peripheral cyclic groups of the boron subphthalocyanine moiety and an axial substituent positioned on the boron atom. The plurality of solubilizing substituents comprise an oxygen or sulfur containing functional group and a substituted or unsubstituted, linear, branched or cyclic, aliphatic or aromatic terminal hydrocarbyl group that is 8 or more carbon atoms in length, the hydrocarbyl group optionally containing one or more heteroatoms. The axial substituent is a cyclic group selected from the group consisting of heterocyclic amine groups, diaryl ketone groups, benzotriazole groups, benzyl alcohol groups and polycyclic aromatic hydrocarbon groups, the cyclic group being bonded to the boron atom by an oxygen containing linking moiety, the cyclic group optionally being substituted with one or more additional substituents.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 5, 2015
    Applicant: XEROX CORPORATION
    Inventors: Jeffrey H. Banning, Wolfgang G. Wedler, Stephan V. Drappel
  • Publication number: 20150057185
    Abstract: Carbon monoxide (CO) is a member of the gasotransmitter family that includes NO and H2S and is implicated in a variety of pathological and physiological conditions. Whereas exogenous therapeutic additions of CO to tissues and whole animals have been well studied, the real-time spatial and temporal tracking of CO at the cellular level remains an open challenge. We now report a new type of turn-on fluorescent probe for selective CO detection by exploiting palladium-mediated carbonylation reactivity. The compounds of the invention are capable of detecting CO both in aqueous buffer and in live cells with high selectivity over a range of biologically relevant reactive small molecules, providing a potentially powerful approach for interrogating its chemistry in biological systems.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 26, 2015
    Inventors: Christopher J. CHANG, Brian William Michel
  • Patent number: 8962155
    Abstract: A light emitting device material containing a pyrromethene compound represented by the general formula (1). It realized a luminescent element having a high luminescent efficiency and exellent color purity. Also provided is a luminescent element employing the materials.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: February 24, 2015
    Assignee: Toray Industries, Inc.
    Inventors: Kazumasa Nagao, Tsuyoshi Tominaga
  • Patent number: 8961656
    Abstract: The present invention relates to an ionic liquid compound that inhibits a formation of a gas hydrate. The compound of the present invention changes an equilibrium temperature and pressure of a gas hydrate in small quantity into a lower temperature and/or a higher pressure, and simultaneously retards the formation of the gas hydrate under the same environment. Thus, the compound of the present invention is used in oil and natural gas industries to effectively inhibit or delay the formation of the gas hydrate under the condition having a low temperature and a high pressure.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: February 24, 2015
    Assignee: Korea Institute of Energy Research
    Inventor: Seong-Pil Kang
  • Publication number: 20150031896
    Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 29, 2015
    Inventors: Horst Vestweber, Holger Heil, Philipp Stoessel, Arne Buesing, Amir Hossain Parham, Rocco Fortte
  • Publication number: 20150018311
    Abstract: The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to C? is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal cappin
    Type: Application
    Filed: January 8, 2013
    Publication date: January 15, 2015
    Applicant: University of Tromsø
    Inventors: Tore Lejon, John Sigurd Svendsen, Alexey Gorovoy, Olga Gozhina
  • Publication number: 20140374724
    Abstract: The present invention relates to a novel indole-based compound having superior hole injection and transport capabilities, light-emitting capabilities, and the like, and an organic electroluminescent device which comprises the indole-based compound in one or more organic layers thereof so as to thereby achieve improved characteristics, such as light-emitting efficiency, driving voltage, and lifespan characteristics.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 25, 2014
    Applicant: DOOSAN CORPORATION
    Inventors: Hoe Moon Kim, Sung Moo Kim, Young Bae Kim, Tae Hyung Kim, Ho Cheol Park, Chang Jun Lee, Young Mi Baek, Jin Yong Shin
  • Publication number: 20140373984
    Abstract: Disclosed are hypergolic salts with borane cluster anions that ignite spontaneously upon contact with nitric acid (from 70% to 100% in water) with short ignition delay. The salts, when added as trigger additive to combustible solvent or ionic liquids, make the resulting formulation hypergolic. The salts with borane cluster anions also shorten ignition delay in hypergols, such as RP-1, and additionally allow nitric acid to be used to replace liquid oxygen as an oxidizer. In some examples, the borane salts are formed in situ in an ionic liquid.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Inventors: Parker D. McCrary, Robin D. Rogers
  • Publication number: 20140371444
    Abstract: Embodiments of the present disclosure provide for methods of making an organoboron compound, organoboron compounds, and the like.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Suzanne A. Blum, Joshua J. Hirner, Darius J. Faizi
  • Publication number: 20140371175
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • Patent number: 8907107
    Abstract: A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O—Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R1, R2, R3, R6, R7, and R8 are each independently H, OH, NO2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water-solubilizing group. At least one of R1, R2, R3 is OH or O-L-X and at least one of R6, R7, and R8 is OH or O-L-X. R4 and R5, which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 9, 2014
    Assignee: Hae Therapeutics Limited
    Inventor: Donal O'Shea
  • Publication number: 20140359794
    Abstract: The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: (I), or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of beta cells, pancreatic islets and microglia cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can also differentiate healthy pancreatic islet cells from diabetic pancreatic islet cells.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 4, 2014
    Inventors: Young-Tae Chang, Sung Chan Lee, Nam-Young Kang, Seong Wook Yun, Cheryl Kit Mun Leong, Hyung Ho Ha
  • Patent number: 8895535
    Abstract: Compounds of the formula I in which R1, R2, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Frank Zenke, Michel Calderini, Djordje Musil
  • Publication number: 20140343019
    Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 20, 2014
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • Patent number: 8889883
    Abstract: The present invention is directed to a fluorescence compound represented by structural Formula (I), with specificity to neural stem cells: I or a pharmaceutically acceptable salt thereof. The variables for structural Formula (I) are defined herein. Also described are methods for detection of neural stem cells, comprising using a compound of structural Formula (I) or pharmaceutically acceptable salts thereof. Compounds of structural Formula (I) can detect and separate neural stem cells without immunostaining, providing a much shorter and more convenient method for detection of neural stem cells.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: November 18, 2014
    Assignees: National University of Singapore, Agency for Science, Technology and Research
    Inventors: Young-Tae Chang, Seong-Wook Yun, Duanting Zhai, Kit Mun Cheryl Leong
  • Patent number: 8865914
    Abstract: The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 21, 2014
    Assignee: The Regents of the University of California
    Inventors: Christopher J. Chang, Genevieve C. Van De Bittner, Tasuku Hirayama, Jefferson Chan
  • Patent number: 8816095
    Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: August 26, 2014
    Assignee: Georgetown University
    Inventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige
  • Publication number: 20140206648
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 24, 2014
    Applicant: REMPEX PHARMACEUTICALS, INC.
    Inventors: Raja K. Reddy, Serge Henri Boyer, Maxim Totrov, Scott Hecker
  • Patent number: 8778510
    Abstract: A pyrromethene-boron complex compound represented by the following formula (1); wherein Z1 and Z2 are independently a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group or a substituted or unsubstituted aryloxy group, at least one of Z1 and Z2 is an alkoxy group substituted with a fluorine atom or an aryloxy group substituted with a fluorine atom or a fluoroalkyl group, and Z1 and Z2 may form a ring.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: July 15, 2014
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Fumio Okuda, Kiyoshi Ikeda, Takayasu Sado, Takahiko Ochi, Yoshimitsu Tanabe, Bunji Sawano
  • Publication number: 20140194387
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: January 13, 2014
    Publication date: July 10, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Publication number: 20140194386
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
  • Publication number: 20140193707
    Abstract: The invention relates to sulfur-containing compounds of the formula I, to their preparation, and to their use as additives in electrochemical or electrooptical devices, more particularly in electrolytes for lithium batteries, lithium ion batteries, double layer capacitors, lithium ion capacitors, solar cells, electrochromic displays, sensors and/or biosensors.
    Type: Application
    Filed: August 22, 2012
    Publication date: July 10, 2014
    Applicant: BASF SE
    Inventors: Michael Schmidt, Nikolai Ignatyev, Guenter Semrau, Walter Frank, Peter Barthen, Christoph Breitenstein
  • Publication number: 20140193849
    Abstract: There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 10, 2014
    Applicant: Agency for Science, Technology and Research
    Inventors: Karthikeyan Narayanan, Andrew Chwee Aun Wan, Jackie Y. Ying, Nandanan Erathodiyil
  • Publication number: 20140186875
    Abstract: The invention relates to compositions and methods useful in the labeling and identification of changes in protein levels, changes in enzyme activity, and changes in protein modification. The invention provides for highly soluble optical labeling molecules which are optionally cleavable after separation of mixtures of labeled proteins into components. These optical labeling molecules find utility in a variety of applications, including use in the field of proteomics.
    Type: Application
    Filed: December 30, 2013
    Publication date: July 3, 2014
    Applicant: Montana State University
    Inventors: Edward Dratz, Paul Grieco